antibacterial, antiproliferative, and cytotoxic activities. The length of the alkyl side chain and the nature of the amino acid residues within the tetramic acid moiety strongly affected activity, in particular against mycobacteria. The mode of action was shown to correlate with the ability of pyreudiones to act as protonophores. Removal of the acidic proton by methylation of pyreudione A resulted in
[EN] 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS<br/>[FR] DÉRIVÉS DE 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHÉNYL)-URÉE UTILISÉS COMME INHIBITEURS DE CXCR2
申请人:GLAXOSMITHKLINE IP DEV LTD
公开号:WO2015181186A1
公开(公告)日:2015-12-03
The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
Bacterial defense mechanisms have evolved to protectbacteriaagainst predation by nematodes, predatory bacteria, or amoebae. We identified novel bacterial alkaloids (pyreudiones A–D) that protect the producer, Pseudomonas fluorescens HKI0770, against amoebal predation. Isolation, structure elucidation, total synthesis, and a proposed biosynthetic pathway for these structures are presented. The generation
An efficient route to the pyrrolizidine ring system via an N-acyl anion cyclisation process
作者:Anthony Murray、George R. Proctor、P.John Murray
DOI:10.1016/0040-4020(96)00049-x
日期:1996.3
An enantioselective route to the pyrrolizidineringsystem has been developed which uses an N-acyl anion cyclisation reaction as the key step. This methodology has provided the natural pyrrolizidines (−)-(1R, 8S)-1-hydroxy-pyrrolizidine 7, (−)-pyrrolizidin-1-ene-3-one 9 and (±)-trachelanthamidine 14. Extension of the process to an N-propionyl substrate provides ready access to a series of 2-methyl
1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors
申请人:GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
公开号:US10106515B2
公开(公告)日:2018-10-23
The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor In addition, the invention relates to compositions containing the derivatives and processes for their preparation.